List of Figures:
Figure 2-1: Global - Biotechnology Market (Billion US$), 2010-2014
Figure 2-2: Biotechnology Market (Billion US$), 2010-2014
Figure 2-3: Share of Public and Private Sector Companies in Biotech Industry (2010)
Figure 2-4: Bio-pharmaceutical Exports (Billion US$), 2005 & 2010
Figure 2-5: Bio-pharmaceutical R&D Expenditure (Billion US$), 2007-2010
Figure 2-6: Farm Scale Revenues from Major Genetically Modified Crops (Billion US$), 2008-2010
Figure 2-7: Ethanol Production (Billion Gallons), 2009-2014
Figure 4-1: Biotech Financing (Billion US$), 2007-2010
Figure 4-2: Biotech Financing by Type (%), 2010
Figure 5-1: Massachusetts - Share in US Biotech Venture Capital Investment (2007-2010)
Figure 5-2: Massachusetts - Number of Drugs under Development Phases
Figure 5-3: New York - Employment in Biotechnology R&D (2007 & 2010)
Figure 6-1: Number of Clinical Trials by Phase (2010)
Figure 6-2: Number of Clinical Trials by Disease Area (2009)
List of Tables:
Table 2-1: Revenues from Public Sector Biotech Companies (Billion US$), 2009 & 2010
Table 2-2: FDA Approvals for Biopharmaceutical (2010)
Table 2-3: Global - Area for Biotech Crops by Major Country (Million Hectare), 2010
Table 2-4: Leading Bio-agricultural Products
Table 3-1: Key M&As in Biotech Industry (2011)
Table 5-1: NIH Funding by State (Million US$), 2010
Table 5-2: Employment in Biotech R&D by State (2007 & 2010)
Table 5-3: Number of Employees in Bio-pharmaceutical Manufacturing by State (2010)
Table 5-4: California - Number of Bio-pharmaceutical Products in Pipeline by Disease Area (2010)
Table 5-5: New York - Status of Bio-science Industry (2010)
Table 5-6: Pennsylvania - Status of Bio-science Industry (2009)
Table 6-1: Number of Clinical Trials by State (2010)
Table 8-1: Amgen - Strengths & Weaknesses
Table 8-2: Biogen Idec - Strengths & Weaknesses
Table 8-3: Baxter International - Strengths & Weaknesses
Table 8-4: Genzyme Corporation - Strengths & Weaknesses
Table 8-5: Monsanto Company - Strengths & Weaknesses
